Apellis Pharmaceuticals, Inc. (APLS) Dividend History

Company News

• Why Apellis Pharmaceuticals Wilted on Wednesday

  Apellis Pharmaceuticals reported a Q1 revenue decline and wider net loss, missing analyst expectations. However, the company continues to develop its drugs Syfovre and Empaveli for new indications, with an FDA decision on Empaveli expected in July.

  The Motley Fool
• Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

  Apellis Pharmaceuticals, a global biopharmaceutical company, announced that it will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025.

  GlobeNewswire Inc.
• Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

  Apellis Pharmaceuticals and Sobi announced that the European Medicines Agency has validated an indication extension application for Aspaveli (pegcetacoplan) to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, two rare kidney diseases with no approved treatments.

  GlobeNewswire Inc.
• Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

  Apellis Pharmaceuticals, Inc. will host a conference call on February 28, 2025, to discuss its fourth quarter and full year 2024 financial results.

  GlobeNewswire Inc.
• Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

  Johnson Fistel, LLP is investigating potential violations of federal and state laws by certain officers of MacroGenics, Apellis Pharmaceuticals, Teradata, and Maplebear. The investigations are related to alleged false and misleading statements made by the companies.

  GlobeNewswire Inc.

  Featured Companies: CART MGNX TDC